Clinical Trials Directory

Trials / Enrolling By Invitation

Enrolling By InvitationNCT07036614

The Novel Special Light for Endotracheal/Bronchial Lesions.

The Application of Novel Special Light in the Diagnosis of Endotracheal/Bronchial Lesions.

Status
Enrolling By Invitation
Phase
Study type
Observational
Enrollment
400 (estimated)
Sponsor
Shanghai Chest Hospital · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

This is a single-center study. The purpose of this study is o evaluate the diagnostic value of special light (TXI, NBI, RDI) in endotracheal/bronchial lesions.

Detailed description

The latest endoscopic system, EVIS X1 (Olympus Medical Systems, Tokyo, Japan), was developed in 2020, which includes brighter and clearer WLI, third-generation (3G)-NBI, texture and color enhancement imaging (TXI) ,and red dichromatic imaging (RDI) as a new image-enhanced endoscopy (IEE) . texture and color enhancement imaging (TXI) as a new image-enhanced endoscopy (IEE). The TXI is designed to enhance the 3 image elements of WLI (texture, brightness, and color) using Retinex-based enhancements while maintaining image naturalness (WLI appearance) clearly defines subtle tissue differences. RDI enables observation of deeper tissue regions by utilizing light of longer wavelengths; such light has weak light scattering characteristics, thus providing the opposite effect of NBI. The original purpose of RDI was to reduce the risk of bleeding during endoscopic treatment by improving the visibility of thick blood vessels in deeper tissues. Although great efforts have been made in exploring the various clinical efficacies of RDI, no published reports have comprehensively covered both the technological and clinical aspects of RDI. The purpose of this study is o evaluate the diagnostic value of special light (TXI, NBI, RDI) in endotracheal/bronchial lesions.

Conditions

Timeline

Start date
2024-01-31
Primary completion
2025-09-30
Completion
2026-09-30
First posted
2025-06-25
Last updated
2025-06-25

Locations

1 site across 1 country: China

Source: ClinicalTrials.gov record NCT07036614. Inclusion in this directory is not an endorsement.